Category Archives: oa.industry

SocArXiv Papers | Dynamics of Cumulative Advantage and Threats to Equity in Open Science – A Scoping Review

Posted on by
Reply

Open Science holds the promise to make scientific endeavours more inclusive, participatory, understandable, accessible, and re-usable for large audiences. However, making processes open will not per se drive wide re-use or participation unless also accompanied by the capacity (in terms of knowledge, skills, financial resources, technological readiness and motivation) to do so. These capacities vary considerably across regions, institutions and demographics. Those advantaged by such factors will remain potentially privileged, putting Open Science’s agenda of inclusivity at risk of propagating conditions of “cumulative advantage”. With this paper, we systematically scope existing research addressing the question: “What evidence and discourse exists in the literature about the ways in which dynamics and structures of inequality could persist or be exacerbated in the transition to Open Science, across disciplines, regions and demographics?” Aiming to synthesise findings, identify gaps in the literature, and inform future research and policy, our results identify threats to equity associated with all aspects of Open Science, including Open Access, Open/FAIR Data, Open Methods, Open Evaluation, Citizen Science, as well as its interfaces with society, industry and policy. Key threats include: stratifications of publishing due to the exclusionary nature of the author-pays model of Open Access; potential widening of the digital divide due to the infrastructure-dependent, highly situated nature of open data practices; risks of diminishing qualitative methodologies as “reproducibility” becomes synonymous with quality; new risks of bias and exclusion in means of transparent evaluation; and crucial asymmetries in the Open Science relationships with industry and the public, which privileges the former and fails to fully include the latter.

Accurate, open data is crucial to cross-sector grid planning and disaster prevention – Geospatial World

Posted on by
Reply

“A particularly promising example of the kind of collective, cross-sector response needed to address this issue comes in the form of utility companies opening grid data up to competitors and even customers. Western Power Distribution has launched an open-access web portal offering detailed data on everything from consumption to generation across its network. The City of London is also working with utility companies to create a combined on-demand digital map of its subterranean pipes and cables where workers can see nearby underground infrastructure on mobile phones or laptop computers before a dig.

Geospatial data on the location and condition of frozen gas pipes could help to protect other underground infrastructure and avert disasters. Data predicting how vegetation growth might impact electricity lines could help a telecoms network operator anticipate potential interference with millimeter waves from nearby 5G antennae. In another example, we are working to integrate IBM Weather Group’s LIDAR and satellite data with geospatial network information to help electrical utilities predict and prevent encroachment on electric transmission and distribution lines….

The trend towards data sharing requires an industry-wide step-change in the capture and curation of data to ensure all companies have a comprehensive, current picture of their networks and use geospatial information systems built around open design principles. This would ensure a consistent standard of network data is captured and shared across the industry. Rich, real-time, and open data can help foster a utility sector built around cooperation that facilitates a higher standard of network resilience despite the challenging environmental issues we face today.”

Joint Statement on transparency and data integrity International Coalition of Medicines Regulatory Authorities (ICMRA) and WHO

Posted on by

“ICMRA1 and WHO call on the pharmaceutical industry to provide wide access to clinical data for all new medicines and vaccines (whether full or conditional approval, under emergency use, or rejected). Clinical trial reports should be published without redaction of confidential information for reasons of overriding public health interest….

Regulators continue to spend considerable resources negotiating transparency with sponsors. Both positive and negative clinically relevant data should be made available, while only personal data and individual patient data should be redacted. In any case, aggregated data are unlikely to lead to re-identification of personal data and techniques of anonymisation can be used….

 

Providing systematic public access to data supporting approvals and rejections of medicines reviewed by regulators, is long overdue despite existing initiatives, such as those from the European Medicines Agency and Health Canada. The COVID-19 pandemic has revealed how essential to public trust access to data is. ICMRA and WHO call on the pharmaceutical industry to commit, within short timelines, and without waiting for legal changes, to provide voluntary unrestricted access to trial results data for the benefit of public health.”

 

 

Frontiers | Open Science for private Interests? How the Logic of Open Science Contributes to the Commercialization of Research | Research Metrics and Analytics

Posted on by

Abstract:  Financial conflicts of interest, several cases of scientific fraud, and research limitations from strong intellectual property laws have all led to questioning the epistemic and social justice appropriateness of industry-funded research. At first sight, the ideal of Open Science, which promotes transparency, sharing, collaboration, and accountability, seems to target precisely the type of limitations uncovered in commercially-driven research. The Open Science movement, however, has primarily focused on publicly funded research, has actively encouraged liaisons with the private sector, and has also created new strategies for commercializing science. As a consequence, I argue that Open Science ends up contributing to the commercialization of science, instead of overcoming its limitations. I use the examples of research publications and citizen science to illustrate this point. Accordingly, the asymmetry between private and public science, present in the current plea to open science, ends up compromising the values of transparency, democracy, and accountability.

 

Promoting versatile vaccine development for emerging pandemics | npj Vaccines

Posted on by

“In this case, the generated knowledge is a clear example of a positive spillover that creates a need for public intervention into the market for research and development. However, this relies on the results of translatable work on prototype pathogens—such as insights into antigen optimisation—being accessible to public use. Therefore, public funding of prototype pathogen work should seek to promote research that generates openly accessible and translatable insights as far as practicable, while also judiciously taking advantage of generating proprietary intellectual property. Even in the cases where a proprietary insight might primarily benefit the originating organisation, such as early preclinical evidence and safety data from clinical trials, the research remains worthy of subsidy because society benefits from having developers that are better prepared to respond to emerging infectious diseases….”

Bill Gates, Vaccine Monster | The New Republic

Posted on by

“Battle-scarred veterans of the medicines-access and open-science movements hoped the immensity of the pandemic would override a global drug system based on proprietary science and market monopolies. By March, strange but welcome melodies could be heard from unexpected quarters. Anxious governments spoke of shared interests and global public goods; drug companies pledged “precompetitive” and “no-profit” approaches to development and pricing. The early days featured tantalizing glimpses of an open-science, cooperative pandemic response. In January and February 2020, a consortium led by the National Institutes of Health and the National Institute of Allergy and Infectious Diseases collaborated to produce atomic-level maps of the key viral proteins in record time. “Work that would normally have taken months—or possibly even years—has been completed in weeks,” noted the editors of Nature. …

By then, however, the optimism and sense of possibility that defined the early days were long gone. Advocates for pooling and open science, who seemed ascendant and even unstoppable that winter, confronted the possibility they’d been outmatched and outmaneuvered by the most powerful man in global public health.

In April, Bill Gates launched a bold bid to manage the world’s scientific response to the pandemic. Gates’s Covid-19 ACT-Accelerator expressed a status quo vision for organizing the research, development, manufacture, and distribution of treatments and vaccines. Like other Gates-funded institutions in the public health arena, the Accelerator was a public-private partnership based on charity and industry enticements. Crucially, and in contrast to the C-TAP, the Accelerator enshrined Gates’s long-standing commitment to respecting exclusive intellectual property claims. Its implicit arguments—that intellectual property rights won’t present problems for meeting global demand or ensuring equitable access, and that they must be protected, even during a pandemic—carried the enormous weight of Gates’s reputation as a wise, beneficent, and prophetic leader. …

“Early on, there was space for Gates to have a major impact in favor of open models,” says Manuel Martin, a policy adviser to the Médecins Sans Frontières Access Campaign. “But senior people in the Gates organization very clearly sent out the message: Pooling was unnecessary and counterproductive. They dampened early enthusiasm by saying that I.P. is not an access barrier in vaccines. That’s just demonstratively false.”…

“Things could have gone either way,” says Love, “but Gates wanted exclusive rights maintained. He acted fast to stop the push for sharing the knowledge needed to make the products—the know-how, the data, the cell lines, the tech transfer, the transparency that is critically important in a dozen ways. The pooling approach represented by C-TAP included all of that. Instead of backing those early discussions, he raced ahead and signaled support for business-as-usual on intellectual property by announcing the ACT-Accelerator in March.” …”

 

Bill Gates, Vaccine Monster | The New Republic

Posted on by

“Battle-scarred veterans of the medicines-access and open-science movements hoped the immensity of the pandemic would override a global drug system based on proprietary science and market monopolies. By March, strange but welcome melodies could be heard from unexpected quarters. Anxious governments spoke of shared interests and global public goods; drug companies pledged “precompetitive” and “no-profit” approaches to development and pricing. The early days featured tantalizing glimpses of an open-science, cooperative pandemic response. In January and February 2020, a consortium led by the National Institutes of Health and the National Institute of Allergy and Infectious Diseases collaborated to produce atomic-level maps of the key viral proteins in record time. “Work that would normally have taken months—or possibly even years—has been completed in weeks,” noted the editors of Nature. …

By then, however, the optimism and sense of possibility that defined the early days were long gone. Advocates for pooling and open science, who seemed ascendant and even unstoppable that winter, confronted the possibility they’d been outmatched and outmaneuvered by the most powerful man in global public health.

In April, Bill Gates launched a bold bid to manage the world’s scientific response to the pandemic. Gates’s Covid-19 ACT-Accelerator expressed a status quo vision for organizing the research, development, manufacture, and distribution of treatments and vaccines. Like other Gates-funded institutions in the public health arena, the Accelerator was a public-private partnership based on charity and industry enticements. Crucially, and in contrast to the C-TAP, the Accelerator enshrined Gates’s long-standing commitment to respecting exclusive intellectual property claims. Its implicit arguments—that intellectual property rights won’t present problems for meeting global demand or ensuring equitable access, and that they must be protected, even during a pandemic—carried the enormous weight of Gates’s reputation as a wise, beneficent, and prophetic leader. …

“Early on, there was space for Gates to have a major impact in favor of open models,” says Manuel Martin, a policy adviser to the Médecins Sans Frontières Access Campaign. “But senior people in the Gates organization very clearly sent out the message: Pooling was unnecessary and counterproductive. They dampened early enthusiasm by saying that I.P. is not an access barrier in vaccines. That’s just demonstratively false.”…

“Things could have gone either way,” says Love, “but Gates wanted exclusive rights maintained. He acted fast to stop the push for sharing the knowledge needed to make the products—the know-how, the data, the cell lines, the tech transfer, the transparency that is critically important in a dozen ways. The pooling approach represented by C-TAP included all of that. Instead of backing those early discussions, he raced ahead and signaled support for business-as-usual on intellectual property by announcing the ACT-Accelerator in March.” …”

 

Opinion | Joe Biden Made a Promise to Scientists. He Can Still Keep It. – The New York Times

Posted on by

“Researchers who receive federal help consistently fail to report their results to the public. The government should hold them accountable….

Researchers using federal funds to conduct cancer trials — experiments involving drugs or medical devices that rely on volunteer subjects — were sometimes taking more than a year to report their results to the N.I.H., as required. “If you don’t report, the law says you shouldn’t get any funding,” he said, citing an investigation I had published in Stat with my colleague Talia Bronshtein. “Doc, I’m going to find out if it’s true, and if it’s true, I’m going to cut funding. That’s a promise.”

It was true then. It’s true now. More than 150 trials completed since 2017 by the N.I.H’s National Cancer Institute, which leads the $1.8 billion Moonshot effort, should have reported results by now. About two-thirds reported after their deadlines or not at all, according to a University of Oxford website that tracks clinical trials regulated by the Food and Drug Administration and National Institutes of Health. Some trial results are nearly two years overdue. Over all, government-sponsored scientists have complied less than half the time for trial results due since 2018. (A spokeswoman for the N.I.H. said, “We are willing to do all measures to ensure compliance with ClinicalTrials.gov results reporting.”)…

In 2016, Dr. Francis Collins, the director of the National Institutes of Health, announced that the agency would begin penalizing researchers for failing to comply with its reporting requirements. “We are serious about this,” he said at the time. Yet in the years since, neither the F.D.A. nor N.I.H. has enforced the law. …”

EU Trials Tracker — Who’s not sharing clinical trial results?

Posted on by

“The best currently available evidence shows that around half of all trials go unreported: this means that doctors and patients see only a partial, biased fraction of the true evidence. We cannot make informed decisions about treatments unless all the data is reported. Under EU rules, from December 2016, all trials on the European Union Clinical Trials Register (EUCTR) should post results within 12 months of completion. There has never been a rule as simple and clear as this, anywhere in the world. Our EU Trials Tracker shows which organisations are compliant, and which aren’t. Our paper in the BMJ analysed the data as of January 2018, and found that only 49% of Europe’s clinical trials reported results in the register.

This website is one of a series of Trials Trackers produced by the EBM DataLab at the University of Oxford….”

EU Trials Tracker — Who’s not sharing clinical trial results?

Posted on by

“The best currently available evidence shows that around half of all trials go unreported: this means that doctors and patients see only a partial, biased fraction of the true evidence. We cannot make informed decisions about treatments unless all the data is reported. Under EU rules, from December 2016, all trials on the European Union Clinical Trials Register (EUCTR) should post results within 12 months of completion. There has never been a rule as simple and clear as this, anywhere in the world. Our EU Trials Tracker shows which organisations are compliant, and which aren’t. Our paper in the BMJ analysed the data as of January 2018, and found that only 49% of Europe’s clinical trials reported results in the register.

This website is one of a series of Trials Trackers produced by the EBM DataLab at the University of Oxford….”

Pistoia Alliance | Collaborate to Innovate Life Science R&D

Posted on by

“We are a global, not-for-profit members’ organization working to lower barriers to innovation in life science and healthcare R&D through pre-competitive collaboration….

The Pistoia Alliance is a global, not-for-profit members’ organization conceived in 2007 and incorporated in 2009 by representatives of AstraZeneca, GSK, Novartis and Pfizer who met at a conference in Pistoia, Italy. This group shared the opinion that life science R&D was changing beyond recognition, and that organizations could not afford to ‘go it alone’ in order to integrate emerging technologies and continue to deliver life-changing therapies to patients. The Pistoia Alliance’s projects help to overcome common obstacles to innovation and to transform R&D – whether identifying the root causes of inefficiencies, working with regulators to adopt new standards, or helping researchers implement AI effectively. There are currently more than 100 member companies – ranging from global organisations, to medium enterprises, to start-ups, to individuals – collaborating as equals on projects that generate value for the worldwide life sciences community….”

Europe hints at patent grab from Big Pharma – POLITICO

Posted on by

“Ever so softly, European politicians are beginning to voice a once unthinkable threat by suggesting they could snatch patents from drug companies to make up for massive shortfalls in the supply of coronavirus vaccines.

Big Pharma businesses have for many years regarded EU countries as unquestioningly loyal allies over intellectual property rights in the international trade arena. The EU could always be relied upon to defend U.S., Japanese and European drugmakers from poor nations in Africa and South Asia that have long wanted the recipe of critical medicines to be handed over to generic manufacturers.

But fury over the inability of companies to deliver on contracts amid the COVID-19 pandemic means that now even European politicians, from the Italian parliament to German Economy Minister Peter Altmaier, are arguing, albeit cautiously, that patents may no longer be as sacrosanct as they once were….”

Full article: Pharmaceutical industry-authored preprints: scientific and social media impact

Posted on by

Abstract

Aim: Non–peer-reviewed manuscripts posted as preprints can be cited in peer-reviewed articles which has both merits and demerits. International Committee of Medical Journal Editors guidelines mandate authors to declare preprints at the time of manuscript submission. We evaluated the trends in pharma-authored research published as preprints and their scientific and social media impact by analyzing citation rates and altmetrics.

Research design and methods: We searched EuroPMC, PrePubMed bioRxiv and MedRxiv for preprints submitted by authors affiliated with the top 50 pharmaceutical companies from inception till June 15, 2020. Data were extracted and analyzed from the search results. The number of citations for the preprint and peer-reviewed versions (if available) were compiled using the Publish or Perish software (version 1.7). Altmetric score was calculated using the “Altmetric it” online tool. Statistical significance was analyzed by Wilcoxon rank-sum test.

Results: A total of 498 preprints were identified across bioRxiv (83%), PeerJ (5%), F1000Research (6%), Nature Proceedings (3%), Preprint.org (3%), Wellcome Open Research preprint (0.2%) and MedRxiv (0.2%) servers. Roche, Sanofi and Novartis contributed 56% of the retrieved preprints. The median number of citations for the included preprints was 0 (IQR =1, Min-Max =0-45). The median number of citations for the published preprints and unpublished preprints was 0 for both (IQR =1, Min-Max =0-25 and IQR =1, Min-Max =0-45, respectively; P?=?.091). The median Altmetric score of the preprints was 4 (IQR =10.5, Min-Max =0-160).

Conclusion: Pharma-authored research is being increasingly published as preprints and is also being cited in other peer-reviewed publications and discussed in social media.

Ten principles for data sharing and commercialization | Journal of the American Medical Informatics Association | Oxford Academic

Posted on by

Abstract:  Digital medical records have enabled us to employ clinical data in many new and innovative ways. However, these advances have brought with them a complex set of demands for healthcare institutions regarding data sharing with topics such as data ownership, the loss of privacy, and the protection of the intellectual property. The lack of clear guidance from government entities often creates conflicting messages about data policy, leaving institutions to develop guidelines themselves. Through discussions with multiple stakeholders at various institutions, we have generated a set of guidelines with 10 key principles to guide the responsible and appropriate use and sharing of clinical data for the purposes of care and discovery. Industry, universities, and healthcare institutions can build upon these guidelines toward creating a responsible, ethical, and practical response to data sharing.

 

Open Call Webinar – Peer Learning Network for Data Collaborations | Register – Contact information

Posted on by

“The Open Data Institute has partnered with Microsoft to launch its Open Data Campaign, which aims to address the data divide and help organisations of all sizes to realise the benefits of data and the new technologies it powers. 

 

As part of the campaign, we’re launching a peer learning network that will convene organisations collaborating around data, providing them with financial and other support from the ODI and Microsoft. Ultimately this will enable them to more effectively address the challenges they face. 

 

On Thursday 29 October 2020, 9:00am PDT/ 4:00pm GMT / 5:00pm CET, join us for a live webinar to learn more about the peer learning network opportunity. We will go over the open call for applications in more detail and provide an opportunity for attendees to ask any related questions before the application deadline (17 November 2020 at 11:59pm PST / 18 November 7:59am GMT (8:59am CET). …”